companies / newlimit-com
Generated UTC · publication cutoff 2026-11-09
Insufficient cited evidence for a two-sentence summary.
NewLimit was listed in 8VC's portfolio, recorded 2026-09-30.
verified=2026-06-07 json
| total_raised | 347,000,000347.0M | ○ |
|---|---|---|
| founded | 2022 | |
| hq | South San Francisco, United States | |
| industry | unknown | |
| stage | series-b+ |
NewLimit is a biotechnology company developing medicines that restore youthful function to old cells by reprogramming the epigenome. It targets patients with age-related diseases of the liver, immune, and vascular systems. Rather than altering DNA, it reverses cellular aging through epigenetic reprogramming guided by single-cell genomics.
No cited completed company acquisition recorded.
Dated disclosures. Customer relationships and classifications are historical; ARR is separate from revenue.
No cited disclosure recorded: named customer, disclosed revenue, ARR, count, B2B / B2C, sector, go-to-market.
No cited valuation with an explicit basis is recorded.
Historical post-money / actual annual or stated TTM revenue. Same currency; economic valuation date within 90 days of revenue period end, inclusive. No FX, ARR, annualized revenue, estimates or projections. Conflicts and ambiguous ties are withheld.
No qualifying pair recorded.
| date | type | amount | lead | src |
|---|---|---|---|---|
| 2025-05-01 | series-b | 130,000,000130.0M | null | ○ |
| investor | src |
|---|---|
| 8VC | ○ |
cloudflare, doubleclick floodlight, google font api, google hosted libraries, hsts, http/3, jquery 3.5.1, mysql, php, vercel speed insights, wordpress
| fact | status | src |
|---|---|---|
| Series B, $130.0M | attributed | ○ |
| Investor 8VC | sourced | WEB |
| existence | self-reported | WEB |
| description | self-reported | WEB |
| date | fact | change | src |
|---|---|---|---|
| 2026-09-30provenance_investor_8vc: unknown → sourced, WEB 2026-09-30 | provenance_investor_8vc | unknown → sourced | WEB 2026-09-30 |
Records begin 2026-09-24. all_changes